These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 34359855)

  • 1. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
    Grassadonia A; Graziano V; Iezzi L; Vici P; Barba M; Pizzuti L; Cicero G; Krasniqi E; Mazzotta M; Marinelli D; Amodio A; Natoli C; Tinari N
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
    Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
    Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
    [No Abstract]   [Full Text] [Related]  

  • 4. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
    BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
    Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting.
    Koh YW; Lee HJ; Ahn JH; Lee JW; Gong G
    Tumour Biol; 2014 Oct; 35(10):9823-30. PubMed ID: 24986572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
    Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
    Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
    [No Abstract]   [Full Text] [Related]  

  • 12. Peripheral Blood Cell Ratios as Prognostic Indicators in a Neoadjuvant Chemotherapy-Treated Breast Cancer Cohort.
    Jalali A; Miresse D; Fahey MR; Ni Mhaonaigh N; McGuire A; Bourke E; Kerin MJ; Brown JAL
    Curr Oncol; 2022 Oct; 29(10):7512-7523. PubMed ID: 36290868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
    Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
    Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?
    Dirican A; Kucukzeybek BB; Alacacioglu A; Kucukzeybek Y; Erten C; Varol U; Somali I; Demir L; Bayoglu IV; Yildiz Y; Akyol M; Koyuncu B; Coban E; Ulger E; Unay FC; Tarhan MO
    Int J Clin Oncol; 2015 Feb; 20(1):70-81. PubMed ID: 24532163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy.
    Bae SJ; Cha YJ; Yoon C; Kim D; Lee J; Park S; Cha C; Kim JY; Ahn SG; Park HS; Park S; Kim SI; Jeong J
    Sci Rep; 2020 Aug; 10(1):13078. PubMed ID: 32753659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer.
    von Au A; Shencoru S; Uhlmann L; Mayer L; Michel L; Wallwiener M; Hennigs A; Deutsch T; Riedel F; Heil J; Golatta M; Schneeweiss A; Schütz F; Domschke C
    Arch Gynecol Obstet; 2023 Apr; 307(4):1105-1113. PubMed ID: 35980458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer.
    Rivas M; Acevedo F; Dominguez F; Galindo H; Camus M; Oddo D; Villarroel A; Razmilic D; Peña J; Munoz Medel M; Navarro ME; Perez-Sepulveda A; Medina L; Merino T; Briones J; Kalergis A; Sanchez C
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2209-2212. PubMed ID: 31350986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.
    Wang H; Huang Z; Xu B; Zhang J; He P; Gao F; Zhang R; Huang X; Shan M
    Clin Transl Oncol; 2024 Jun; 26(6):1467-1479. PubMed ID: 38190034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
    Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
    Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.